Abstract YO16
Case summary
Thai male patient, 58 years old
He had been diagnosed essential hypertension and dyslipidemia for over 10 years (2005) and received cadaveric donor kidney transplantation on Oct 2005.
In May 2017, he presented with left hip closed fracture, in plain film of Lt hip had showed osteolytic lesion at left head and neck of femur with fracture at intertrochanter of femur.
He received bone biopsy and result showed metastatic clear cell renal cell carcinoma.
On CT chest and whole abdomen include pelvis had seen heterogeneous enhancing mass at right native kidney size 7.1 x 7.2 x 8.5 cm with synchronous lesion at transplanted kidney size 1.1 x 1.4 cm and pathological lymph nodes at internal iliac artery, no distance metastasis.
He underwent surgery to debulk tumor and hemiarthroplasty of left hip and received post-operative radiotherapy. Post-operative, he had been added everolimus 0.5 mg per day.
He starts treatment with Pazopanib since June 2007 until now and has hand foot syndrome grade I, diarrhea grade I, his blood pressure is well controlled and now he still has partial response.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
313P - Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019
Presenter: Jo Pai Chen
Session: Poster display session
Resources:
Abstract
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract